Australian goods imported into the US will continue to attract the baseline 10% tariff, with Australia dodging any tariff increase in the latest round of Donald Trump’s global trade war.
On Thursday night US time – Friday morning in Australia – Trump issued an executive order confirming new tariff deals for several trading partners, as well as revised tariffs for a number of other countries.
Australia is not mentioned in the order, which stated that any countries not on the new list would remain at a 10% tariff. Guardian Australia understands the US government confirmed to the Australian embassy in Washington DC that the 10% tariff rate would remain in place.
“The White House has confirmed that no country has reciprocal tariffs lower than Australia,” a spokesperson for Australia’s minister for trade, Don Farrell, said on Friday morning.
Trump’s so-called “reciprocal tariffs” are separate to the industry-specific tariffs of 50% imposed by the Trump administration on Australian steel, aluminium and copper imports: those tariffs also remain in place.
Sign up: AU Breaking News email
“While we remain in the best possible position under the United States’ new tariff regime, we will continue to advocate for the removal of all tariffs in line with our free trade agreement,” the spokesperson said.
In the executive order issued this week, Trump indicated he was open to further negotiations on tariffs with countries he saw as aligned to his America First ideology.
“Some trading partners have agreed to, or are on the verge of agreeing to, meaningful trade and security commitments with the United States, thus signaling their sincere intentions to permanently remedy the trade barriers that have contributed to the national emergency declared in Executive Order 14257, and to align with the United States on economic and national security matters.”
Executive Order 14257 was Trump’s April order, which argued that “large and persistent annual US goods trade deficits constitute an unusual and extraordinary threat to the national security and economy of the United States”.
Trump’s latest executive order castigated unnamed countries he felt had shown insufficient fealty to the US on trade.
“Other trading partners, despite having engaged in negotiations, have offered terms that, in my judgment, do not sufficiently address imbalances in our trading relationship or have failed to align sufficiently with the United States on economic and national-security matters,” the order read.
“There are also some trading partners that have failed to engage in negotiations with the United States or to take adequate steps to align sufficiently with the United States on economic and national security matters.”
The new executive order punishes small economies in particular, who have limited trading relationships with the US: Syria was given a 41% tariff rate, Myanmar and Laos 40%.
The EU has a split tariff rate: 0% on some goods, and 15% on others.
China, one of the US’s largest trading partners and a target of Trump’s trade ire, is not mentioned in the latest order. It remains at a 30% tariff rate, with some exemptions for goods such as smartphones and semiconductors. A proposed – punitive – 145% tariff on Chinese imports has been paused until mid-August.
The US treasury secretary, Scott Bessent, told reporters the US has the “makings of a deal” with China, but that it’s not yet complete.
“There’s still a few technical details to be worked out on the Chinese side between us. I’m confident that it will be done, but it’s not 100% done.”
With tariff negotiations still in play, Trump has taken aim at countries that negotiate with American drug companies to pay lower prices for pharmaceuticals, such as Australia.
Under Australia’s Pharmaceutical Benefits Scheme, the government negotiates directly with drug companies to secure comparatively low prices, a longstanding arrangement, but one which has been a consistent irritant for Trump.
Australia has been consistent in its dealings with the Trump administration that “the PBS is not up for negotiation”.
“Our government is getting on with the job of delivering cheaper medicines for Australians,” a government spokesperson said.
